SCHEMBL20914084

SCHEMBL20914084

COc1cccc2oc(-c3c(C(=O)NCc4cc[nH]n4)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 2/20 0.33
▸ F2RL3 Q96RI0 2/20 0.33
▸ PDE4B Q07343 3/20 0.32
▸ TACR1 P25103 2/20 0.32
▸ CNR2 P34972 1/20 0.31
▸ PDE11A Q9HCR9 2/20 0.31
▸ MAPT P10636 1/20 0.31
▸ PDE2A O00408 1/20 0.31
▸ MAT2A P31153 1/20 0.31
▸ DGAT1 O75907 1/20 0.31
▸ KLKB1 P03952 1/20 0.31
▸ HPGD P15428 2/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ APLNR P35414 1/20 0.30
▸ TOP2A P11388 1/20 0.30
▸ HSD17B10 Q99714 2/20 0.30
▸ USP2 O75604 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914000 0.89 F2RL3 (0.33) ADORA2AF2RL3PDE4BTACR1MAT2A
SCHEMBL20818972 0.88 NPC1 (0.35) ADORA2AF2RL3DGAT1HPGDKDM4E
SCHEMBL20914008 0.88 TAAR1 (0.33) ADORA2AF2RL3PDE4BPDE2AMAT2A
SCHEMBL20837044 0.88 F2RL3 (0.33) ADORA2AF2RL3PDE4BTACR1PDE2A
SCHEMBL20837252 0.86 FYN (0.36) F2RL3DGAT1KDM4EALDH1A1HSD17B10
SCHEMBL20914027 0.86 PTGER1 (0.36) ADORA2AF2RL3PDE4BCNR2PDE2A
SCHEMBL20819040 0.86 TNKS (0.35) ADORA2AF2RL3KDM4EALDH1A1APLNR
SCHEMBL20913994 0.85 POLB (0.37) ADORA2AF2RL3MAPTKDM4EALDH1A1
SCHEMBL20914091 0.84 TNKS (0.34) F2RL3MAPTKDM4EALDH1A1TOP2A
SCHEMBL20913950 0.84 PDE4B (0.35) ADORA2AF2RL3PDE4BMAPTPDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 ADORA2A 1285/4885F2RL3 1469/4885PDE4B 190/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 ADORA2A 1285/4885F2RL3 1469/4885PDE4B 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback